Ernexa Therapeutics Inc.
ERNA
$0.2047
-$0.0033-1.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 582.00K | 598.00K | 162.00K | 115.00K | 68.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 582.00K | 598.00K | 162.00K | 115.00K | 68.00K |
| Cost of Revenue | 96.00K | 162.00K | 342.00K | 247.00K | 236.00K |
| Gross Profit | 486.00K | 436.00K | -180.00K | -132.00K | -168.00K |
| SG&A Expenses | 13.32M | 16.13M | 16.80M | 15.50M | 14.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.83M | 20.92M | 22.15M | 21.26M | 20.74M |
| Operating Income | -17.25M | -20.32M | -21.99M | -21.15M | -20.68M |
| Income Before Tax | -44.51M | -44.92M | -23.93M | -22.90M | -21.67M |
| Income Tax Expenses | 30.00K | 15.00K | -5.00K | -4.00K | -3.00K |
| Earnings from Continuing Operations | -44.54 | -44.93 | -23.92 | -22.90 | -21.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.54M | -44.93M | -23.92M | -22.90M | -21.67M |
| EBIT | -17.25M | -20.32M | -21.99M | -21.15M | -20.68M |
| EBITDA | -17.11M | -20.18M | -21.86M | -21.04M | -20.59M |
| EPS Basic | -7.32 | -8.31 | -4.42 | -4.25 | -4.08 |
| Normalized Basic EPS | -2.19 | -2.79 | -2.77 | -2.61 | -2.50 |
| EPS Diluted | -7.32 | -8.31 | -4.42 | -4.25 | -4.08 |
| Normalized Diluted EPS | -2.19 | -2.79 | -2.77 | -2.61 | -2.50 |
| Average Basic Shares Outstanding | 54.59M | 21.64M | 21.64M | 21.54M | 21.25M |
| Average Diluted Shares Outstanding | 54.59M | 21.64M | 21.64M | 21.54M | 21.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.02% | -0.04% | -0.07% | -0.07% | -0.07% |